Dr. Carmen E. Demarco, MD

Dr. Demarco practices at Corewell Health William Beaumont University Hospital in Royal Oak, Michigan, part of Corewell Health.

Dr. Demarco's NPI, 1790808616, was assigned on April 7, 2007. Dr. Demarco holds Michigan license 4301074802.

Dr. Demarco's primary practice is Corewell Health William Beaumont University Hospital, at 3601 W Thirteen Mile Rd, Royal Oak, MI 48073 in Oakland County. The practice phone is (248) 898-5400.

Dr. Demarco's primary practice is Corewell Health William Beaumont University Hospital in Royal Oak, Michigan, part of Corewell Health. Dr. Demarco is also affiliated with Corewell Health Farmington Hills Hospital. The medical group on file is Beaumont Medical Group - Specialty Services. Dmand AI also links Dr. Demarco to 1 more physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Demarco practices, 4 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Demarco's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Demarco is licensed in Michigan.

CMS data shows 163 Medicare services from Dr. Demarco across 5 procedure codes in 2024, for 91 Medicare patients. Medicare paid $14,342 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 91 Medicare patients who saw Dr. Demarco in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 33% are also on Medicaid. Their average risk score is 3.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Demarco's median patient age at 62, with 51% women.

In 2024, Dr. Demarco wrote 306 Medicare Part D claims for 45 patients. 90% of them were for generic drugs. CMS names the drug for 212 of them, across 8 drugs with 11 or more claims each, at $77,358 in total drug cost. In 2023, CMS named 313 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Demarco for performance year 2024, reported as part of a group. Dr. Demarco accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Demarco, published from 2014 to 2024. Dr. Demarco's most frequent co-authors are Matthew M. Churpek, MD, PhD, Alon Dagan, MD and Karthik V. Iyer, MD.

Dmand AI links Dr. Demarco to 1 clinical trial. Conditions studied include Clostridium Infections and Gram-Positive Bacterial Infections.

CMS Open Payments shows 30 general payments to Dr. Demarco from 9 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $300.